Management

With the bold aspiration of bringing curative drug therapies and visionary healthcare solutions to patients worldwide, Mr. Mauvernay is president of Après-demain, the parent company of Debiopharm, a Swiss, privately owned, biopharmaceutical company founded by his father over 40 years ago. Debiopharm, with 15 ongoing drug research programs, has developed two blockbuster therapies for cancer patients, oxaliplatin and triptorelin, along with a potential 3rd Head & Neck Cancer drug currently in phase III development with an international partner.  The holding company, Après-demain, invests in a variety of industries including companies impacting sustainable energy, food, & healthcare along with real estate, via 30+ direct investments in companies as well as LP investments in more than 100 funds globally. In addition, Mr. Mauvernay brings strategic insights to the Debiopharm Innovation Fund as the chairman of the investment committee, backed by his experience as an entrepreneur in the international cosmetics industry before joining his family’s drug development business and asset diversification activities. His educational background includes a Master of Science in Economics and Marketing along with an MBA from the 'Institut d'Administration des Entreprises’.

Dr. Ducrey is CEO of Debiopharm and Senior Vice-Chairman of the Life Science activities of Après-demain, a privately-owned, mid-size biopharmaceutical company focusing on the development of novel oncology and infectious disease therapies. The Swiss based company leverages expertise in drug development, drug formulation and drug delivery within a unique business model that connects discovery research products from start-ups and universities to larger pharmaceutical companies who make medicines available to patients worldwide. His role englobes the management of the various Life Science activities of Debiopharm including drug development, drug formulation & manufacturing and digital health investment. Having joined Debiopharm in 1995, his work in various roles has contributed to two blockbuster therapies for cancer patients, oxaliplatin and triptorelin, along with a potential 3rd blockbuster drug currently in phase III research in Head & Neck cancer with an international partner. Debiopharm’s pipeline includes 15 ongoing programs in various stages of development with the aim of curing cancer and infectious diseases through innovative cellular targets and novel modes of action. His educational background includes the School of Pharmacy of Lausanne University, Switzerland followed by a Ph.D. in Pharmaceutical Sciences.

Angela Zubel obtained her MD from Jagiellonian University Krakow, Poland, and her PhD from the German Cancer Research Center (DKFZ) in Heidelberg, Germany. Before joining the pharmaceutical industry, Angela worked for several years as a physician and investigator at the Gynecology and Oncology Department of the Clinical University Hospital in Krakow, Poland. She worked several years as a Medical Leader at MerckSerono where she was responsible for Cetuximab late clinical development. She then spent several years at Novartis as Clinical Program Leader responsible for various oncology programs in early clinical development and as a deputy Site Head Translational Clinical Oncology in Basel. She subsequently held the position of Clinical Development Unit Head, Biopharmaceuticals at Sandoz. Angela joined Debiopharm International in February 2019.

Dr Lévy obtained his doctoral degree at the Karolinska Institute in Stockholm and spent several years as a postdoctoral fellow at the California Institute of Technology. He moved then to Lausanne to take a leadership position at the Ludwig Institute for Cancer Research, where he was awarded a Young Investigator Award of the Cancer Research Institute, a Professorship of the Swiss National Funds and an Associate Professorship of the University of Lausanne. He joined Debiopharm International in 2008 and has held several management positions before becoming Director, Head of Search & Evaluation and Scientific Innovation in 2018. He is also a member of the Scientific Advisory Board of Eclosion in Geneva.

Vanessa Currat holds a Master of Business Law ("DESS") from the University of Paris V - René Descartes and a Master of International Economical Law from Paris I – La Sorbonne ("DEA"). She has more than 20 years of management experience in the biopharma industry with particular expertise in: negotiation of licensing and acquisition deals, Intellectual Property management including strategy conception and implementation, risk management, competition, corporate and labor law. She also has a successful track record in handling worldwide commercial and patent litigations. Prior responsibilities include positions at Kimbrough & Associates, Alcatel-Lucent, Vetrotech, and Debiotech. She joined Debiopharm International SA in 1996 where she served as lawyer and IP Counsel, becoming IP Manager in 2000. Since implementing the merge of the IP and Legal Services departments in 2006, she has been the head of Legal Affairs of Debiopharm Group. She joined the Executive Committee in 2014.

Pierre obtained his Master degree in Business Administration and Finance at Dauphine-University (Paris, France) in 2000. Pierre started his career in 2000 at Air Liquide - world leader in gases, technologies and services for Industry and Health - in Corporate Finance, Mergers & Acquisitions, and Strategic planning activities. He moved into pharma in 2008 joining Ipsen, a global listed biotech focused on Specialty Care, where he held Finance Director Positions for Belgium, France and then VP Finance for Global R&D to support the commercial development and the portfolio management. Pierre Jullian joined Debiopharm in 2018.

Mrs Perraudin obtained a Degree in International Relations from the Graduate Institute of International Studies in 1992 and a Master of Business Administration from the IMD, in 2002. With 21 years’ experience in Human Resources, she has held several senior management positions in the medical technology, hi-tech and engineering industries. She spent seven years at Medtronic Europe as Human Resources Director of the European Cardiovascular Division, subsequently held the position of Corporate Vice President Human Resources at Advanced Digital Broadcast and then became the Global Division Vice President Human Resources at IMI Hydronics, an organization including 6 manufacturing sites and 2000 employees in Europe, Asia and America. She joined Debiopharm International in 2014.

Nicolas Favre obtained his PhD from University of Geneva, Switzerland and his MBA from the OU Business school in the UK. Nicolas started his career in R&D in inflammation and oncology at Merck Serono. He then moved to commercial positions, first focusing on patient adherence to treatment at Aardex group and then on branding and brand name development at Brand Institute. Then, Nicolas moved to Denmark where he successively worked in Global Marketing on Azilect® at Lundbeck and on Levemir® at Novo Nordisk where he launched several campaigns and led key LCM initiatives of these multi-billion dollar brands. Since 2016, Nicolas joined Debiopharm where he first held the position in Product Marketing for triptorelin, before taking on the responsibility of Market Access. Today, Nicolas oversees Commercial and Business Development including Communication, Licensing, Marketing, Market Intelligence, Market Access & Medical Affairs activities.

With the bold aspiration of bringing curative drug therapies and visionary healthcare solutions to patients worldwide, Mr. Mauvernay is president of Après-demain, the parent company of Debiopharm, a Swiss, privately owned, biopharmaceutical company founded by his father over 40 years ago. Debiopharm, with 15 ongoing drug research programs, has developed two blockbuster therapies for cancer patients, oxaliplatin and triptorelin, along with a potential 3rd Head & Neck Cancer drug currently in phase III development with an international partner.  The holding company, Après-demain, invests in a variety of industries including companies impacting sustainable energy, food, & healthcare along with real estate, via 30+ direct investments in companies as well as LP investments in more than 100 funds globally. In addition, Mr. Mauvernay brings strategic insights to the Debiopharm Innovation Fund as the chairman of the investment committee, backed by his experience as an entrepreneur in the international cosmetics industry before joining his family’s drug development business and asset diversification activities. His educational background includes a Master of Science in Economics and Marketing along with an MBA from the 'Institut d'Administration des Entreprises’.

Dr. Ducrey is CEO of Debiopharm and Senior Vice-Chairman of the Life Science activities of Après-demain, a privately-owned, mid-size biopharmaceutical company focusing on the development of novel oncology and infectious disease therapies. The Swiss based company leverages expertise in drug development, drug formulation and drug delivery within a unique business model that connects discovery research products from start-ups and universities to larger pharmaceutical companies who make medicines available to patients worldwide. His role englobes the management of the various Life Science activities of Debiopharm including drug development, drug formulation & manufacturing and digital health investment. Having joined Debiopharm in 1995, his work in various roles has contributed to two blockbuster therapies for cancer patients, oxaliplatin and triptorelin, along with a potential 3rd blockbuster drug currently in phase III research in Head & Neck cancer with an international partner. Debiopharm’s pipeline includes 15 ongoing programs in various stages of development with the aim of curing cancer and infectious diseases through innovative cellular targets and novel modes of action. His educational background includes the School of Pharmacy of Lausanne University, Switzerland followed by a Ph.D. in Pharmaceutical Sciences.

Nicolas Py received his Master’s degree in Cellular Biology and Molecular Genetics from the universities of Versailles and Paris-Sud in 1997, then graduated as an Engineer in Life Sciences and Applied Biochemistry from AgroParisTech Institute in 2000, and completed his education with a Master’s degree in Marketing and Management from EM Strasbourg Business School in 2003. He started his career in 2000 as an analyst at ADIT, a consulting company specialized in Competitive Intelligence (Paris and Strasbourg, France). In 2003, he joined the Business Development department of Transgene (Strasbourg, France), a listed biopharmaceutical company focused on developing targeted immunotherapies. From 2004 to 2007, he worked as Competitive Intelligence analyst at Air Liquide Group (Paris, France), the world leader in gases, technologies and services for industry and health. He joined Debiopharm in 2007 and he is now Director, Head of Market Intelligence.

Michele Antonelli has a master degree in Plant Biology from the University of Bari, Italy. He qualified the ENI’s (Italian National Oil Company) postgraduate programme in Biotechnology and Advanced Genetics at the Catholic University in Piacenza, Italy and at the Iowa State University Ames, Iowa, USA. From 1982 to 1992, he worked at Enichem, Italy as Research fellow and then as Head of Molecular and Cell Biology Unit. In 1992, he joined Serono in Geneva, Switzerland, where he held several senior managerial positions in Quality, Product and Process Development and Industrial Manufacturing in Biotechnology, and as Senior Vice President Biotech Manufacturing and Process Development. In 2008, Mr. Antonelli joined UCB as Executive Vice President Technical Operations & Quality Assurance. In 2012 he joined the European Commercial Operations team as Executive Vice President & Managing Director of UCB France. In November 2015 he joint Stallergenes SAS as the Executive Vice President, Head of International Operations. Since February 2016, Mr. Antonelli is the President of Stallergenes SAS and Executive Vice President, Head of Europe & Rest of World.

Mr. Belingard graduated from ‘Ecole des Hautes Etudes Commerciales (HEC) Paris (1971), and he holds a Master of Business Administration (MBA) from Cornell University, USA (1974). Since then, Mr. Belingard has held many management positions at Merck, Sharp and Dohme (Sales and Marketing Director, 1974-1981, Senior Director, Promotion Planning, 1981-1983), Roche France (“President du Directoire”, 1983-1990), F. Hoffman-La Roche Ltd. (Member of the Executive Committee, 1990-1998), Roche Diagnostics, Basel (Chief Executive Officer, 1990-1998), bioMerieux-Pierre Fabre (Chief Executive Officer, 1999-2001), Ipsen Group (Chairman and Chief Executive Officer, 2002-2010). In January 2011, Mr. Belingard was appointed Chairman and Chief Executive Officer of bioMérieux.

François Crémieux received his Master’s degree from Paris-Dauphine and Lancaster (UK) universities in 1994. He then received a Master degree in public health from Paris Diderot Medical School and graduated in hospital management from the French school of public health (EHESP). After working for the United-Nations and the World Health Organization in different post conflict environments including as CEO of the hospital in Mitrovica (Kosovo), Mr. Crémieux's career had been focused on hospital management in France. He was the Director of the Hotel-Dieu hospital in Paris from 2008 to 2010. He then became the director of hospitals and clinics for the Greater Paris health authority overseeing over 70 separate institutions from 2010 to 2012 before joining the cabinet of the French Minister for Social Affairs and Health from 2012 to 2014. Since 2014, Mr. Crémieux has been the CEO of the northern Paris University hospitals. Mr. Crémieux is a member of the committee as an expert on behalf of the Greater Paris University Hospitals (AP-HP). He receives no personal compensation for his contributions to the committee.